To evaluate the efficiency and the safety of Shufeng Jiedu Capsules for treating acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:A comprehensive and systematic search was carried out in 7 Chinese and English databases in CNKI，VIP，Wanfang，Sinomed，Embase，Medline，and Cochrane Library，and the randomized controlled trial(RCT)of Shufeng Jiedu Capsules in the treatment of AECOPD was screened.The search time limit was from the establishment of each database to May 2019.According to the pre-set inclusion and exclusion criteria，a total of 2 researchers independently screened the literature，extracted data，evaluated the quality of the included RCTs combined with the “Cochrane Bias Risk Assessment” tool，and RevMan 5.3 software was used for the included studies to perform Meta quantitative analysis.Results:A total of 13 RCTs involving 989 patients were included.Among them，there were 494 cases in the test group(conventional Western medicine treatment+Shufeng Jiedu Capsules)and 495 cases in the control group(conventional Western medicine treatment).Meta-analysis results indicated that the test group was superior to the control group in total efficacy ［RR=1.25，95%CI(1.16 to 1.35)，P<0.000 01］，increasing PaO2 ［MD=5.65，95%CI(4.22 to 7.07)，P<0.000 01］and reducing PaCO2 ［MD=-2.70，95%CI(-3.88 to -1.53)，P<0.000 01］，and decreased the level of inflammatory factors including IL-8 ［MD=-8.29，95%CI(-9.48 to -7.10)，P<0.000 01］，TNF-α(TNF-α)［MD=-6.30，95%CI(-7.11 to -5.49)，P<0.000 01］.There was no significant difference in adverse reactions between the test group and the control group ［OR=1.43，95%CI(0.44 to 4.61)，P=0.55］.Conclusion:Based on available evidence，Shufeng Jiedu Capsules combined with conventional Western medicine treatment can improve the clinical efficacy of AECOPD，without serious adverse reactions.However，because the quality of the included studies is generally low and the number is small，and there are many limitations such as publication bias，which affects the reliability of the conclusions.Thus its effectiveness and safety still need more rigorous design and high-quality RCT tests to improve the evidence quality level.